| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Technical Advances |
From the Departments of Pathology, Brigham and Women's Hospital
and Harvard Medical School *
and the Dana-Farber Cancer
Institute,
Boston, Massachusetts
Nonrandom chromosomal aberrations, particularly in cancer, identify pathogenic biological pathways and, in some cases, have clinical relevance as diagnostic or prognostic markers. Fluorescence and colorimetric in situ hybridization methods facilitate identification of numerical and structural chromosome abnormalities. We report the development of robust, unique-sequence in situ hybridization probes that have several novel features: 1) they are constructed from multimegabase contigs of yeast artificial chromosome (YAC) clones; 2) they are in the form of adapter-ligated, short-fragment, DNA libraries that may be amplified by polymerase chain reaction; and 3) they have had repetitive sequences (eg, Alu and LINE elements) quantitatively removed by subtractive hybridization. These subtracted probes are labeled conveniently, and the fluorescence or colorimetric detection signals are extremely bright. Moreover, they constitute a stable resource that may be amplified through at least four rounds of polymerase chain reaction without diminishing signal intensity. We demonstrate applications of subtracted probes for the MYC and EWS oncogene regions, including 1) characterization of a novel EWS-region translocation in Ewing's sarcoma, 2) identification of chromosomal translocations in paraffin sections, and 3) identification of chromosomal translocations by conventional bright-field microscopy.
This article has been cited by other articles:
 |
|
 |
|
  A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists J. Mol. Diagn., November 1, 2008; 10(6): 527 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, R. Bhargava, T. Zheng, L. Wexler, M. H. Collins, D. Roulston, and M. Ladanyi Undifferentiated Small Round Cell Sarcomas with Rare EWS Gene Fusions: Identification of a Novel EWS-SP3 Fusion and of Additional Cases with the EWS-ETV1 and EWS-FEV Fusions J. Mol. Diagn., September 1, 2007; 9(4): 498 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish International Journal of Surgical Pathology, October 1, 2005; 13(4): 343 - 351. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Laack, H. Nikbakht, A. Peters, C. Kugler, Y. Jasiewicz, L. Edler, J. Brummer, U. Schumacher, and D. K. Hossfeld Expression of CEACAM1 in Adenocarcinoma of the Lung: A Factor of Independent Prognostic Significance J. Clin. Oncol., November 1, 2002; 20(21): 4279 - 4284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Hecht and J. C. Aster Molecular Biology of Burkitt's Lymphoma J. Clin. Oncol., November 1, 2000; 18(21): 3707 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanner, D. Gancberg, A. Di Leo, D. Larsimont, G. Rouas, M. J. Piccart, and J. Isola Chromogenic in Situ Hybridization : A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples Am. J. Pathol., November 1, 2000; 157(5): 1467 - 1472. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
